Can tongue power predict better eating after mouth cancer surgery?
NCT ID NCT07390942
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study will measure tongue strength and biting force in 40 mouth cancer patients who use a special plate called an obturator to help them swallow. Researchers want to see how these measurements relate to what patients eat each day. The goal is to better understand how to improve eating ability and quality of life after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could point toward better dietary advice and rehabilitation strategies to help maxillectomy patients eat more easily.
- What could go wrong
- This is a small, early observational study with only 40 participants, so results may not apply to all patients. It measures physical performance, not a treatment, so direct benefits are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIETARY BEHAVIOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Dentistry of National Taiwan University Hospital
Taipei, 100, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Magnet vs. pin: which prosthesis connector feels better after maxillectomy?
- Can a glowing drug light up head and neck tumors?
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.
- New tracheostomy tube holder aims to cut infections and boost comfort
- HIV and cancer: study seeks to uncover hidden risk factors
- New drug combo targets HPV-Driven cancers in phase II trial